Newswire (Published: Tuesday, May 14, 2019, Received: Tuesday, May 14, 2019, 4:33:42 PM CDT)

Word Count: 342

2019 MAY 14 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- LINTHICUM, Md. and ARLINGTON, Va., The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) announced updates to their joint clinical guideline on adjuvant and salvage radiotherapy after prostatectomy in patients with and without evidence of prostate cancer recurrence to include new published research related to adjuvant radiotherapy.

The Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline (available online in the Journal of Urology and in Practical Radiation Oncology) was amended as follows:

In addition to the guideline statements, new information related to genomic classifiers, as predictors of treatment effectiveness, was added to the guideline future research needs. Further study in this area is needed to determine whether a genomic classifier is predictive of outcomes in a yet to be treated patient, and whether it is predictive for efficacy of a particular treatment.

“Evidence from three, well-established randomized trials now confirm significant improvements in biochemical recurrence-free survival among patients with adverse pathological features with the use of adjuvant radiotherapy,” said Ian Thompson, MD, co-chair of the guideline panel and professor and chairman of the urology division at the University of Texas Health Sciences Center at San Antonio, Texas. “Our expectation is this guideline is fully aligned to the latest science and provides physicians with a relevant blueprint for the use of radiotherapy after prostatectomy.”

“As research in prostate cancer evolves and improves, data continue to accumulate in support of radiotherapy following radical prostatectomy. We now know that radiotherapy and the combination of hormone therapy with radiation, following radical prostatectomy, have contributed to even more favorable outcomes for patients than seen previously,” said Richard K. Valicenti, MD, FASTRO, co-chair of the guideline panel and professor and chairman of radiation oncology at the University of California-Davis Comprehensive Cancer Center in Sacramento, California. “With the current update, this collaborative guideline now reflects nearly three decades of multidisciplinary research.”

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

American Society For Radiation Oncology

Industries

Biotechnology
      Biopharmaceuticals
Pharmaceuticals
      Biopharmaceuticals

Places

North America
United States
Americas
California
Texas
Virginia
Sacramento
San Antonio
Arlington

Subjects

Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Radiology
            Urology
      Treatments and Therapies
            Radiation Therapy